Literature DB >> 12136894

Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients.

Franco Franceschini1, Ilaria Cavazzana, Daniele Generali, Marzia Quinzanini, Luigi Viardi, Anna Ghirardello, Andrea Doria, Roberto Cattaneo.   

Abstract

OBJECTIVE: To assess the clinical and serological associations of anti-Ku antibodies.
METHODS: Fourteen patients with anti-Ku antibody detected by counterimmunoelectrophoresis (CIE) and immunoblot (IB) were retrospectively evaluated.
RESULTS: Patients (13 women, one man) had a mean age of 60.3 years (range 19-83). Seven patients had overlap syndromes: 5 polymyositis/scleroderma (PM/SSc), one systemic lupus erythematosus (SLE)/SSc/PM, and one SLE/PM. Three additional patients had undifferentiated connective tissue disease, 2 primary Sjögren's syndrome (SS), one psoriatic arthritis, and one SSc. The clinical manifestations most frequently recorded were arthralgias (86%), myositis (50%) and Raynaud's phenomenon (78.6%). Five patients had esophageal dysmotility, while 6 showed interstitial pulmonary fibrosis (4 of them with reduced DLCO). No case of pulmonary hypertension was observed. All patients had very high titer of ANA with speckled and nucleolar pattern. All the sera were positive for anti-Ku antibodies by CIE: all but one were confirmed by IB. Eight sera contained isolated antibodies to Ku proteins: both subunits were recognized in 7 cases, while isolate reactivity to the 70 kDa protein was detected in one case. Five sera contained additional antibody specificities: anti-Ro 60 kDa in 4 cases, and anti-La/SSB, anti-SL, and anti-PM-Scl in one case each.
CONCLUSION: Anti-Ku antibody is found in a wide spectrum of connective tissue diseases including overlap syndromes with SSc and myositis. Raynaud's phenomenon and muscular and joint involvement are the most frequent clinical features associated with anti-Ku antibodies, which are frequently detected in association with anti-Ro/SSA and/or other antinuclear specificities.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12136894

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  The olfactory function is impaired in patients with idiopathic inflammatory myopathies.

Authors:  L Iaccarino; N Shoenfeld; M Rampudda; M Zen; M Gatto; A Ghirardello; N Bassi; L Punzi; Y Shoenfeld; A Doria
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Cutting edge issues in polymyositis.

Authors:  Anna Ghirardello; Sandra Zampieri; Elena Tarricone; Luca Iaccarino; Luisa Gorza; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

Review 3.  Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.

Authors:  Yasuhito Hamaguchi; Kazuhiko Takehara
Journal:  J Scleroderma Relat Disord       Date:  2018-07-10

4.  Serologic phenotypes distinguish systemic lupus erythematosus patients developing interstitial lung disease and/or myositis.

Authors:  Thaisa Cotton; Marvin J Fritzler; May Y Choi; Boyang Zheng; Omid Zahedi Niaki; Christian A Pineau; Luck Lukusa; Sasha Bernatsky
Journal:  Lupus       Date:  2022-08-26       Impact factor: 2.858

5.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

6.  The clinical phenotype of patients positive for antibodies to myositis and myositis-related disorders.

Authors:  S G Gofrit; H Yonath; M Lidar; Y Shoenfeld; S Kivity
Journal:  Clin Rheumatol       Date:  2018-02-16       Impact factor: 2.980

Review 7.  Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.

Authors:  Linda Nalotto; Luca Iaccarino; Margherita Zen; Mariele Gatto; Elisabetta Borella; Marta Domenighetti; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 8.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

9.  The phenotype of myositis patients with anti-Ku autoantibodies.

Authors:  Maria Casal-Dominguez; Iago Pinal-Fernandez; Assia Derfoul; Rose Graf; Harlan Michelle; Jemima Albayda; Eleni Tiniakou; Brittany Adler; Sonye K Danoff; Thomas E Lloyd; Lisa Christoper-Stine; Julie J Paik; Andrew L Mammen
Journal:  Semin Arthritis Rheum       Date:  2021-04-28       Impact factor: 5.431

Review 10.  Autoantibodies in polymyositis and dermatomyositis.

Authors:  Anna Ghirardello; Nicola Bassi; Lavinia Palma; Elisabetta Borella; Marta Domeneghetti; Leonardo Punzi; Andrea Doria
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.